Repaglinide versus metformin in controlling post-prandial hyperglycemia in type II diabetics

Abstract EN

Background : Metformin is a well known anti-diabetic agent, Repaglinide is a new insulin secretagogues. Objective : Is to compare between Repaglinide and Metformin in controlling post- prandial hyperglycemia in type II diabetics. Design : cross –sectional randomized clinical study. Patients and Methods : patients with type II diabetes are randomly divided into 2 groups [ each group contain 25 patients], 1st group patients were already on 1 mg Repaglinide twice daily 10 minutes before meal, 2nd group patients were already on 500 mg Metformin twice daily immediately after meal., for each patient , 2hrs post –prandial blood sugar was done . Results : The average post-prandial blood sugar in patients taking Repaglinide was [172.22 Mg / dl] ± SEM [1.22] [ range of blood sugar was 127 mg / dl – 170 mg / dl ], while the average post-prandial blood sugar in patients taking Metformin was [169.28 mg / dl] with SEM [1.63] [range of blood sugar was 153 mg / dl-186 mg / dl], independent T-test was done which revealed no significant difference between Repaglinide and Metformin in controlling post-prandial hyperglycemia [p > o.o5]. Conclusion and Recommendation : there is no significant difference between Repaglinide and Metformin in controlling post-prandial hyperglycemia in type II diabetics and further studies to evaluate cost-effectiveness and cardio-vascular risk reduction of both drugs are needed.